Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 717

1.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
[PubMed - indexed for MEDLINE]
Free Article
2.

Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.

Antivir Ther. 2004 Oct;9(5):713-9.

PMID:
15535408
[PubMed - indexed for MEDLINE]
3.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group.

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897
[PubMed - indexed for MEDLINE]
Free Article
4.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M.

AIDS. 2000 Mar 31;14(5):499-507.

PMID:
10780712
[PubMed - indexed for MEDLINE]
5.

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.

Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr.

AIDS. 2007 Apr 23;21(7):825-34.

PMID:
17415037
[PubMed - indexed for MEDLINE]
6.

The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.

Klein MB, Willemot P, Murphy T, Lalonde RG.

AIDS. 2004 Sep 24;18(14):1895-904.

PMID:
15353975
[PubMed - indexed for MEDLINE]
7.

Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS.

HIV Med. 2006 Jul;7(5):311-6.

PMID:
16945076
[PubMed - indexed for MEDLINE]
8.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
[PubMed - indexed for MEDLINE]
9.

The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.

Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, Minoli L, Sighinolfi L, Nasta P, Suter F; MASTER Data Base Cohort.

Antivir Ther. 2006;11(7):923-9.

PMID:
17302255
[PubMed - indexed for MEDLINE]
10.

Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

Patel N, Abdelsayed S, Veve M, Miller CD.

Ann Pharmacother. 2011 Mar;45(3):317-24. doi: 10.1345/aph.1P576. Epub 2011 Mar 8.

PMID:
21386025
[PubMed - indexed for MEDLINE]
11.

Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.

de la Rosa R, Ruíz-Mateos E, Rubio A, Abad MA, Vallejo A, Rivero L, Genebat M, Sánchez-Quijano A, Lissen E, Leal M.

J Antimicrob Chemother. 2004 Jan;53(1):95-101. Epub 2003 Dec 4.

PMID:
14657091
[PubMed - indexed for MEDLINE]
Free Article
12.

Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.

Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.

PMID:
20156097
[PubMed - indexed for MEDLINE]
13.

Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.

Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.

Clin Infect Dis. 2005 Nov 1;41(9):1326-32. Epub 2005 Sep 29.

PMID:
16206110
[PubMed - indexed for MEDLINE]
Free Article
14.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
[PubMed - indexed for MEDLINE]
15.

Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.

Mtambo A, Chan K, Shen A, Lima V, Hogg R, Montaner J, Moore D.

HIV Med. 2012 Mar;13(3):141-7. doi: 10.1111/j.1468-1293.2011.00950.x. Epub 2011 Nov 22.

PMID:
22107262
[PubMed - indexed for MEDLINE]
16.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
[PubMed - indexed for MEDLINE]
17.

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.

Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test.

Antivir Ther. 2006;11(5):553-60.

PMID:
16964822
[PubMed - indexed for MEDLINE]
18.

Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

HIV Med. 2007 Mar;8(2):80-5.

PMID:
17352763
[PubMed - indexed for MEDLINE]
19.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(5):585-91.

PMID:
16152752
[PubMed - indexed for MEDLINE]
20.

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).

Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, Tomino C, Vella S; ISS-IP1 study group.

HIV Med. 2004 Jan;5(1):1-10.

PMID:
14731162
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk